NASDAQ:ZVRA Zevra Therapeutics (ZVRA) Stock Price, News & Analysis → Tech GIANT’s Plans to Revolutionize Crypto… (From Crypto 101 Media) (Ad) Free ZVRA Stock Alerts $4.89 +0.07 (+1.45%) (As of 05/13/2024 ET) Add Compare Share Share Today's Range$4.75▼$5.0550-Day Range$4.50▼$6.3152-Week Range$3.89▼$7.28Volume355,318 shsAverage Volume245,040 shsMarket Capitalization$204.65 millionP/E RatioN/ADividend YieldN/APrice Target$19.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Zevra Therapeutics alerts: Email Address Zevra Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside298.8% Upside$19.50 Price TargetShort InterestBearish6.15% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.70Based on 18 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.60) to ($0.17) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.95 out of 5 starsMedical Sector824th out of 925 stocksPharmaceutical Preparations Industry391st out of 430 stocks 3.5 Analyst's Opinion Consensus RatingZevra Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageZevra Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Zevra Therapeutics' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted6.15% of the float of Zevra Therapeutics has been sold short.Short Interest Ratio / Days to CoverZevra Therapeutics has a short interest ratio ("days to cover") of 10.6, which indicates bearish sentiment.Change versus previous monthShort interest in Zevra Therapeutics has recently increased by 11.81%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldZevra Therapeutics does not currently pay a dividend.Dividend GrowthZevra Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ZVRA. Previous Next 2.6 News and Social Media Coverage News SentimentZevra Therapeutics has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 18 news articles for Zevra Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 4 people have searched for ZVRA on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Zevra Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Zevra Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.40% of the stock of Zevra Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 35.03% of the stock of Zevra Therapeutics is held by institutions.Read more about Zevra Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Zevra Therapeutics are expected to grow in the coming year, from ($1.60) to ($0.17) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Zevra Therapeutics is -3.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Zevra Therapeutics is -3.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioZevra Therapeutics has a P/B Ratio of 2.86. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Zevra Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaTech GIANT’s Plans to Revolutionize Crypto…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About Zevra Therapeutics Stock (NASDAQ:ZVRA)Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.Read More ZVRA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ZVRA Stock News HeadlinesMay 11 at 1:22 AM | americanbankingnews.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Expected to Earn Q2 2024 Earnings of ($0.44) Per ShareMay 10 at 4:16 AM | americanbankingnews.comFY2027 EPS Estimates for Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Boosted by Roth CapitalMay 9, 2024 | finance.yahoo.comZevra Therapeutics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagMay 9, 2024 | finance.yahoo.comZevra Therapeutics to Participate at Upcoming Investor EventsMay 9, 2024 | finance.yahoo.comZevra Therapeutics Inc (ZVRA) (Q1 2024) Earnings Call Transcript Highlights: Navigating ...May 8, 2024 | finance.yahoo.comZevra Therapeutics Inc (ZVRA) Q1 2024 Earnings: Misses EPS Estimates, Revenue Consistent with ...May 8, 2024 | investorplace.comZVRA Stock Earnings: Zevra Therapeutics Beats EPS, Misses Revenue for Q1 2024May 8, 2024 | globenewswire.comZevra Therapeutics Reports First Quarter 2024 Financial Results and Corporate UpdatesMay 6, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRAMay 1, 2024 | globenewswire.comZevra Therapeutics to Report First Quarter 2024 Results on May 8, 2024April 29, 2024 | finance.yahoo.comZevra Therapeutics’ President and Chief Executive Officer Issues Letter to Stockholders Highlighting Recent Key Accomplishments and Outlook for 2024April 28, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRAApril 20, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRAApril 15, 2024 | globenewswire.comZevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual MeetingApril 12, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRAApril 10, 2024 | globenewswire.comZevra Therapeutics Refinances Existing Debt with up to $100M in Committed Capital under New Credit FacilityApril 10, 2024 | globenewswire.comZevra Therapeutics Refinances Existing Debt with up to $100M in Committed Capital under New Credit FacilityApril 4, 2024 | finance.yahoo.comZevra Therapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS LagsApril 4, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRAApril 3, 2024 | markets.businessinsider.comZevra Therapeutics: Poised for Transformation and Growth Amidst Market OverreactionApril 3, 2024 | finance.yahoo.comBearish: Analysts Just Cut Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Revenue and EPS estimatesApril 2, 2024 | stockhouse.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRAApril 1, 2024 | insidermonkey.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Q4 2023 Earnings Call TranscriptMarch 31, 2024 | finance.yahoo.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Just Reported, And Analysts Assigned A US$18.25 Price TargetMarch 30, 2024 | seekingalpha.comZevra Therapeutics, Inc. (ZVRA) Q4 2023 Earnings Call TranscriptSee More Headlines Receive ZVRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zevra Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/28/2024Today5/13/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ZVRA CUSIPN/A CIK1434647 Webwww.kempharm.com Phone(321) 939-3416Fax319-665-2577Employees65Year FoundedN/APrice Target and Rating Average Stock Price Target$19.50 High Stock Price Target$25.00 Low Stock Price Target$15.00 Potential Upside/Downside+298.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-46,050,000.00 Net Margins-181.76% Pretax Margin-176.46% Return on Equity-82.55% Return on Assets-35.84% Debt Debt-to-Equity Ratio0.88 Current Ratio2.10 Quick Ratio2.10 Sales & Book Value Annual Sales$27.46 million Price / Sales7.45 Cash FlowN/A Price / Cash FlowN/A Book Value$1.71 per share Price / Book2.86Miscellaneous Outstanding Shares41,850,000Free Float40,849,000Market Cap$204.65 million OptionableOptionable Beta1.87 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Neil F. McFarlane (Age 51)President, CEO & Director Comp: $503.77kMs. Christal M. M. Mickle M.A. (Age 45)Co-Founder & Chief Development Officer Comp: $622.36kMr. R. LaDuane Clifton CPA (Age 52)CFO, Secretary & Treasurer Comp: $658.43kMr. Joshua M. Schafer M.B.A. (Age 52)Chief Commercial Officer & Executive VP of Business Development Comp: $766.07kDr. Sven Guenther Ph.D. (Age 52)Chief Scientific Officer Comp: $497.26kMs. Nichol L. OchsnerVice President of Investor Relations & Corporate CommunicationsDr. Christopher M. Lauderback Ph.D. (Age 49)Senior Vice President of Manufacturing Dr. Rene A. Braeckman Ph.D.Senior Vice President of Clinical DevelopmentDr. Daniel Gallo Ph.D.Senior Vice President of Medical Affairs & AdvocacyDr. Adrian Quartel FFPM (Age 63)M.D., Chief Medical Officer More ExecutivesKey CompetitorsG1 TherapeuticsNASDAQ:GTHXPuma BiotechnologyNASDAQ:PBYIuniQureNASDAQ:QUREMerrimack PharmaceuticalsNASDAQ:MACKEmergent BioSolutionsNYSE:EBSView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 58,866 shares on 5/10/2024Ownership: 3.924%Retirement Planning Co of New England Inc.Bought 42,766 shares on 5/7/2024Ownership: 0.991%Mystic Asset Management Inc.Bought 35,514 shares on 5/7/2024Ownership: 0.613%SG Americas Securities LLCSold 8,319 shares on 5/7/2024Ownership: 0.029%Janney Montgomery Scott LLCSold 23,262 shares on 5/1/2024Ownership: 1.520%View All Insider TransactionsView All Institutional Transactions ZVRA Stock Analysis - Frequently Asked Questions Should I buy or sell Zevra Therapeutics stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zevra Therapeutics in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ZVRA shares. View ZVRA analyst ratings or view top-rated stocks. What is Zevra Therapeutics' stock price target for 2024? 6 Wall Street research analysts have issued twelve-month target prices for Zevra Therapeutics' stock. Their ZVRA share price targets range from $15.00 to $25.00. On average, they expect the company's share price to reach $19.50 in the next twelve months. This suggests a possible upside of 298.8% from the stock's current price. View analysts price targets for ZVRA or view top-rated stocks among Wall Street analysts. How have ZVRA shares performed in 2024? Zevra Therapeutics' stock was trading at $6.55 at the start of the year. Since then, ZVRA stock has decreased by 25.3% and is now trading at $4.89. View the best growth stocks for 2024 here. When is Zevra Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our ZVRA earnings forecast. How were Zevra Therapeutics' earnings last quarter? Zevra Therapeutics, Inc. (NASDAQ:ZVRA) released its quarterly earnings results on Thursday, March, 28th. The company reported ($0.40) EPS for the quarter, missing analysts' consensus estimates of ($0.20) by $0.20. The firm earned $13.22 million during the quarter, compared to analysts' expectations of $13.35 million. Zevra Therapeutics had a negative net margin of 181.76% and a negative trailing twelve-month return on equity of 82.55%. Who are Zevra Therapeutics' major shareholders? Zevra Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (3.92%), Janney Montgomery Scott LLC (1.52%), Retirement Planning Co of New England Inc. (0.99%), Mystic Asset Management Inc. (0.61%), IFG Advisors LLC (0.04%) and SG Americas Securities LLC (0.03%). Insiders that own company stock include Corey Michael Watton, John B Bode, Joshua Schafer, Matthew R Plooster, R Laduane Clifton, Richard W Pascoe, Tamara A Seymour and Timothy J Sangiovanni. View institutional ownership trends. How do I buy shares of Zevra Therapeutics? Shares of ZVRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ZVRA) was last updated on 5/13/2024 by MarketBeat.com Staff From Our PartnersThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBill Clinton Backing Biden Replacement???The Freeport SocietyTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeThe Crypto 9-5 Escape PlanCrypto 101 MediaExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zevra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
